Mycenax Biotech Inc. (4726.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$22.45 (+0.00%) as of
Key statistics
- Market cap
- 4.65B
- EPS (TTM)
- -1.85
- Dividend yield
- 0.00%
- 52-week range
- 22.10 – 37.00
- Beta
- 0.44
- Revenue (TTM)
- 815.87M
- Profit margin
- -46.81%
- Volume
- 40.42k
About Mycenax Biotech Inc.
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.